Correspondence
Research Letter
Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients

https://doi.org/10.1053/j.ajkd.2016.01.011Get rights and content

Section snippets

Acknowledgements

Support: None.

Financial Disclosure: Two authors report receipt of consulting fees (RMinutolo: Roche and Menarini; LDN: AbbVie, Merck, and Bristol Myers Squibb). DR has received honoraria for lectures for AbbVie, Amgen, Janssen, Kerix, Genzyme, and Shire. The remaining authors declare that they have no relevant financial interests.

Contributions: Research idea/study design: RMinutolo, LDN, DR; data acquisition: MB, SS, CA, GC, CM, OF, DS, RMusacchio, PI, FF; data analysis/interpretation:

References (10)

There are more references available in the full text version of this article.
View full text